Prescription Drug CPI

Drug prices almost never fall. The prescription drug component of the Consumer Price Index has been positive for roughly 95 percent of the past thirty years, with annual gains typically between 2 and 5 percent. The curve is persistent and predictable.

It broke. BLS data shows the year-over-year change at -2.2 percent as of March 2026. That is the kind of deflation the index produces only during specific regulatory interventions, and this one has two of them running at the same time. Medicare negotiation on a widening list of drugs is feeding through to the price indexes. Generic substitution on several high-volume brand franchises is arriving in parallel.

This is a genuine bright spot, rare enough in the Cost Pressure set that it deserves naming. But the relief is concentrated in the drugs that are on-patent-coming-off and in the categories Medicare is negotiating. Patients on novel biologics, weight-loss drugs, or specialty cancer therapies face price curves that look nothing like the headline number.

The broader context is sobering. Medical Care CPI is still running above 3 percent. Doctor visits, hospital services, and insurance premiums are doing the work of keeping total healthcare inflation positive. Drug deflation is helpful. It's also the smallest line in the medical budget for most households who aren't on a specialty therapy.